Compare ASTL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | CGEM |
|---|---|---|
| Founded | 1902 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 794.7M |
| IPO Year | N/A | 2020 |
| Metric | ASTL | CGEM |
|---|---|---|
| Price | $3.55 | $12.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.11 |
| AVG Volume (30 Days) | ★ 1.3M | 756.0K |
| Earning Date | 03-11-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.68 | $79.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.02 | $5.68 |
| 52 Week High | $7.25 | $16.74 |
| Indicator | ASTL | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 40.60 |
| Support Level | $3.54 | $11.43 |
| Resistance Level | $4.77 | $13.21 |
| Average True Range (ATR) | 0.27 | 0.83 |
| MACD | -0.09 | -0.38 |
| Stochastic Oscillator | 12.98 | 1.27 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.